While the news flow is slowing from the JP Morgan Healthcare Conference the presentations continue with United Health Care earnings report coming tomorrow.
Some notable headlines:
Health Catalyst has signed an agreement to acquire Upfront Healthcare Services that anticipates closing in Q1 of 2025 with a mix of cash and stock for $86M. Health Catalyst presents on Wednesday
Nvidia announces AI partnerships with IQVIA, Illumina, and the Mayo Clinic. This includes solutions to help speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring, and operations
Teledoc announces partnership with Amazon for customers eligible for Teladoc Health’s diabetes, hypertension, prediabetes and weight management program to seamlessly disvoer and enroll in these benefits available through their employer or health plan at no additional cost through Amazon’s health benefits connector
Neogenomics (NEO) announced 4Q results ahead of expectations.
McKesson (MCK) reaffirms FY25 outlook.
Certera (CERT) announced preliminary 4Q results ahead of expectations.
Optinose (OPTN) announced 4Q XHANCE revenue ahead of expectations.
Keros Therapeutics has announced the early termination of its Phase 2 TROPOS trial for cibotercept (KER-012) in patients with pulmonary arterial hypertension (PAH) due to safety concerns, specifically pericardial effusion adverse events. All dosing, including placebo, has been halted, and patients will be monitored through end-of-trial visits. The company plans to present topline data from all treatment arms in Q2 2025.
